Democritus University of Thrace (DUTH)
Επιγενετικές μεταβολές με προγνωστική και προβλεπτική σημασία στο cell-free DNA (cfDNA) ασθενών με πρώιμο και προχωρημένο καρκίνο του στομάχου
Abstract
dc:descriptionGastric cancer is one of the most common cancers in the world. The average age of diagnosis is 69 years and the 5-year overall survival at any stage, is less than 30%. The outcome of advanced gastric cancer remains unfavorable. Its etiology is multifactorial. Dietary habits and H. pylori infection play the most important role in the development of this disease. The most common symptoms include weight loss, dysphagia, nausea, abdominal pain, and melaenae. Treatment of the disease includes surgical excision, chemotherapy (preoperative, perioperative, postoperative, as well as chemotherapy/targeted treatment in metastatic disease) as well as radiotherapy. Prognosis of gastric cancer remains poor. Epigenetics refers to inherited changes in gene expression that are not due to modifications in the DNA sequence. The most well-known epigenetic marker is DNA methylation. During carcinogenesis, there is generally hypomethylation of several genes, but in particular there is hypermethylation of tumor suppressor genes. DNA-based biomarkers have been developed using cell-free DNA (cfDNA) in patient's blood, in order to diagnose and predict the response to cancer treatment. Until now, this feature is not applicable on a large scale. Recent advances in understanding cancer-related DNA methylation have resulted in the use of this method at clinical level, with the development of molecular indicators for early diagnosis and prognosis of cancer. The ability of methylation markers to detect cancer has been tested in several biological samples, including blood. Gene methylation plays an important role in the development of gastric cancer. In addition, hypermethylation of many genes with different biological functions has been correlated with clinicopathological features and prognosis of gastric cancer. In the present study, the methylation status of the tumor suppressor genes RASSF1A, SOX17, Wif-1, BRCA1 and BRCA2 in the cfDNA of patients with advanced gastric cancer, was determined in 105 patients with metastatic gastric cancer as well as in 63 patients with early gastric cancer at the department of Medical Oncology in the University General Hospital of Alexandroupolis. The results of this study are:•Concentration of cfDNA in blood sasmples of patients with metastatic gastric cancer is higher than that of healthy controls.•In patients with metastatic gastric cancer, the promoter region of RASSF1A, SOX17, Wif-1, BRCA1 and BRCA2 genes was found to be methylated to a fairly high percentage.•Methylation of the promoter region of these genes is associated with a decrease in progression free survival (PFS).•Methylation of the promoter region of all genes studied is associated with a decrease in overall survival (OS).•Methylation all genes studied, except the Wif-1 gene is associated with a decreased response to first-line treatment containing docetaxel, capecitabine and oxaliplatin.More studies are needed for the establishment of hypermethylation of the RASSF1A, SOX17, Wif-1, BRCA1 and BRCA2 tumor suppressor genes, as powerful biomarkers for the early diagnosis, prognosis and prediction of response to chemotherapy in patients with early and advanced gastric cancer.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Karamitrousis, Evangelos
- Καραμητρούσης, Ευάγγελος
Subjects
dc:subject × 25- Μεθυλίωση
- Ογκοκατασταλτικό γονίδιο
- Καρκίνος
- Καρκίνος στομάχου
- Προγνωστική αξία
- Προβλεπτική αξία
- Ελεύθερο κυττάρων DNA
- Methylation
- Tumor suppressor gene
- Cancer
- Gastric cancer
- Stomach cancer
- Prognostic significance
- Predictive significance
- Cell-free DNA
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Φαρμακολογία και Φαρμακευτική
- Κλινική Ιατρική
- Ογκολογία
- Basic Medicine
- Medical and Health Sciences
- Pharmacology and Pharmacy
- Clinical Medicine
- Oncology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/50195